Vedolizumab
Discovery
Development
Clinical
Filed
Commercialized
Therapeutic area
Therapeutic area
Gastroenterology, Immunology
Reference product
Reference product
Entyvio® (Takeda)
Commercial partners
Commercial partners
Fresenius-Kabi, MS Pharma
Status
Status
Filed
About this program
Vedolizumab is a biosimilar developed to match Entyvio®, a reference biologic used in the treatment of Ulcerative Colitis, Crohn's Disease and Inflammatory Bowel Disease.
Commercialization partners
Fresenius-Kabi
US
US
RoW outside Middle East
MS-Pharma
Middle East
Let's build together.
If you want to explore what a partnership with us could look like, we're ready to talk.